Abstract
Despite the advancements in diagnosis and therapy for hepatocellular carcinoma (HCC) that currently permit to treat with tailored strategies the disease in early stages, for intermediate and advanced stages the therapeutic options are far from optimal. In recent years, new targets have been searched by exploring the molecular pathways involved in hepatocarcinogenesis, leading to multiple trials on new agents interfering in these mechanisms.
In this article we revised the principal agents that raised major interest, from the one already established as gold standard for advanced HCC (sorafenib) to the new molecules still in preclinical or early clinical studies. The extensive investigation on the field will identify the best agents and the subsets of patients that will benefit most from their application.
Keywords: Hepatocellular carcinoma, kinase inhibitors, molecular therapy, signal pathways, treatment, Sorafenib, Organ- Specific Drug, Bevacizumab, Vatalanib, Sunitinb, Cediranib, SU6668, Dovitinib, Brivanib, ABT 869, Cetuximab, Gefitinib, Erlotinib, Lapatinib, ABT-100, Rapamycin, Everolimus, VEGF, TGF, EGF, IGFs, FGF, HGF
Current Signal Transduction Therapy
Title: New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Volume: 6 Issue: 2
Author(s): Fabio Farinati, Nora Cazzagon, Anna Giacomin and Anna
Affiliation:
Keywords: Hepatocellular carcinoma, kinase inhibitors, molecular therapy, signal pathways, treatment, Sorafenib, Organ- Specific Drug, Bevacizumab, Vatalanib, Sunitinb, Cediranib, SU6668, Dovitinib, Brivanib, ABT 869, Cetuximab, Gefitinib, Erlotinib, Lapatinib, ABT-100, Rapamycin, Everolimus, VEGF, TGF, EGF, IGFs, FGF, HGF
Abstract: Despite the advancements in diagnosis and therapy for hepatocellular carcinoma (HCC) that currently permit to treat with tailored strategies the disease in early stages, for intermediate and advanced stages the therapeutic options are far from optimal. In recent years, new targets have been searched by exploring the molecular pathways involved in hepatocarcinogenesis, leading to multiple trials on new agents interfering in these mechanisms.
In this article we revised the principal agents that raised major interest, from the one already established as gold standard for advanced HCC (sorafenib) to the new molecules still in preclinical or early clinical studies. The extensive investigation on the field will identify the best agents and the subsets of patients that will benefit most from their application.
Export Options
About this article
Cite this article as:
Farinati Fabio, Cazzagon Nora, Giacomin Anna and Anna , New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795660034
DOI https://dx.doi.org/10.2174/157436211795660034 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model
Current Cancer Drug Targets Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Poly(ADP-ribose) Polymerase-1 Inhibitor 3-Aminobenzamide Enhances Apoptosis Induction by Platinum Complexes in Cisplatin-Resistant Tumor Cells
Medicinal Chemistry Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy
Current Medicinal Chemistry Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry The Therapeutic Potential of Targeting Autophagy in the Treatment of Cancer
Current Cancer Drug Targets HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Current Drug Targets Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Non Alcoholic Fatty Liver: Epidemiology and Natural History
Reviews on Recent Clinical Trials MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3
Current Molecular Medicine Bioactive Compounds Effective Against Type 2 Diabetes Mellitus: A Systematic Review
Current Topics in Medicinal Chemistry Synthesis, Cytotoxic and Heparanase Inhibition Studies of 5-oxo-1-arylpyrrolidine-3- carboxamides of Hydrazides and 4-amino-5-aryl-4H-1,2,4-triazole-3-thiol
Current Organic Synthesis Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design